AlCana Technologies

By Doug Macron
AlCana Technologies last month denied that its researchers violated non-compete agreements with their former employer, Tekmira Pharmaceuticals, as part of a legal claim filed against it by that company.

According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.

Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.

Alnylam will have the exclusive rights to all new inventions resulting from the alliance, as well as the rights to sublicense any related intellectual property. Tekmira will have the right to use new inventions with its own RNAi therapeutics.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.